Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
Abstract To compare outcomes in patients with human epidermal growth factor receptor-2 (HER2)-positive breast cancer who received either dose-dense neoadjuvant chemotherapy (NAC) with trastuzumab or standard-interval chemotherapy with trastuzumab. Patients with HER2-positive breast cancer who receiv...
| Main Authors: | , , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Nature Portfolio
2021-06-01
|
| 叢編: | npj Breast Cancer |
| 在線閱讀: | https://doi.org/10.1038/s41523-021-00284-y |